QIAGEN Reports Strong Fourth Quarter and Fiscal...

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this 
announcement. 
----------------------------------------------------------------------
--------------    




*          35% Constant Currency and 13% Organic Revenue Growth in
  2008
*          54% Growth in Adjusted Operating Income in 2008
*          47% Growth in Adjusted Net Income in 2008

Venlo, The Netherlands, February 9, 2009 - QIAGEN N.V. (Nasdaq: QGEN;
Frankfurt, Prime Standard: QIA) today announced preliminary unaudited
results of  operations for  the fourth  quarter and  the fiscal  year
ended December 31, 2008.

The reported net sales exceeded, and adjusted earnings per share  for
the fourth  quarter and  fiscal 2008  were  on the  high end  of  the
guidance provided by the Company on November 11, 2008.

Fourth Quarter 2008 Results
The Company  reported  that consolidated  net  sales for  its  fourth
quarter 2008 increased 13% to $237.2 million from $210.2 million  for
the same quarter in 2007.  Reported operating income for the  quarter
increased 62% to $40.4 million from $25.0 million in the same quarter
of 2007,  and net  income  for the  quarter  increased 65%  to  $24.7
million from  $15.0 million  in  the same  quarter of  2007.  Diluted
earnings per share for the fourth quarter increased to $0.12 in  2008
(based on 202.0 million weighted average shares and share equivalents
outstanding) from  $0.07 in  2007 (based  on 205.2  million  weighted
average shares and share equivalents outstanding).

On an adjusted basis, fourth  quarter operating income increased  29%
to $66.6  million in  2008 from  $51.8 million  in 2007,  and  fourth
quarter 2008 adjusted net income increased 36% to $43.7 million  from
$32.0 million in 2007. Adjusted diluted earnings per share  increased
to $0.22  in the  fourth quarter  of 2008  from $0.16  in the  fourth
quarter of 2007.

QIAGEN's fourth  quarter and  fiscal year  2007 results  include  the
results of operations  of Digene  Corporation and  eGene, Inc.,  from
their dates of  acquisition, July  2007, as well  as certain  charges
related to  these acquisitions.  QIAGEN's fourth  quarter and  fiscal
year 2008 results include the  results of operations of Corbett  Life
Science  and  the  BioSystems  business  of  Biotage  AB  from  their
respective dates  of acquisition,  July 2008  and October  2008,  and
Digene Corporation and eGene, Inc. for the entire period, as well  as
certain charges related to these acquisitions.


Fiscal Year 2008 Results


QIAGEN's Fiscal 2008

in $ millions, except per share      FY 2008      FY 2007      Growth
information
Net sales                              893.0        649.8         37%
Operating income, adj. [1]             252.7        164.3         54%
Net income, adj.[1], [2]               163.3        111.5         47%
EPS, adj.[1], [2] ($)                   0.80         0.63         27%

[1] excluding business integration and restructuring related charges
as well as amortization of acquired intangibles and equity-based
compensation.
[2] including a non-cash tax benefit of $0.02 per share in 2007 and
including a non-cash tax charge of $0.01 per share from revaluation
of acquired tax positions in 2008.



For the year  ended December  31, 2008,  net sales  increased 37%  to
$893.0 million compared to $649.8  million in 2007. Operating  income
as reported  for fiscal  2008 increased  75% to  $145.7 million  from
$83.1 million for 2007, and net income increased 78% to $89.0 million
in 2008 from $50.1  million in 2007, and  diluted earnings per  share
increased to $0.44 in 2008  (based on 204.3 million weighted  average
shares and share equivalents outstanding)  from $0.28 in 2007  (based
on 176.0  million  weighted  average  shares  and  share  equivalents
outstanding).

On an adjusted basis,  operating income for  the year ended  December
31, 2008,  increased 54%  to $252.7  million from  $164.3 million  in
2007, and adjusted net income increased 47% to $163.3 million in 2008
from $111.5 million in 2007. Adjusted diluted earnings per share  for
the year ended December 31, 2008,  increased 27% to $0.80 per  share,
from $0.63 per share in 2007.

QIAGEN has  regularly reported  adjusted results  to give  additional
insight into its financial performance as well as considered  results
on a constant currencies basis. Adjusted results should be considered
in addition  to  the reported  results  prepared in  accordance  with
generally  accepted  accounting   principles,  but   should  not   be
considered as a substitute. The Company believes certain items should
be excluded from adjusted results when they are either outside of our
ongoing core  operations or  can vary  significantly from  period  to
period, which affects the comparability of results with the Company's
competitors and our  own prior  periods. Costs  and charges  excluded
from   adjusted    results   include    business   integration    and
restructuring-related   costs   as   well   as    acquisition-related
amortization,  and  equity  based  compensation  in  accordance  with
Statement of Financial Accounting  Standards No. 123 (Revised)  (SFAS
123R).



QIAGEN's Adjustments to Gross Profit,
Operating Income, Net Income and EPS

in $ millions unless    Q4 2008     Q4 2007     FY 2008     FY 2007
indicated

Gross profit,               157.5       138.8       599.7       433.5
reported
Acquistion related            1.0         1.5         1.4         2.8
charges
Amortization of              13.2        11.3        48.7        23.7
acquired intangibles
SFAS 123R impact              0.2         0.3         1.0         0.4
Gross profit,               171.9       151.9       650.8       460.4
adjusted

Operating income,            40.4        25.0       145.7        83.1
reported
Acquistion related            1.0         1.5         1.4         2.8
charges (COS)
Business integration          4.4         8.1        30.9        14.9
and related costs
Purchased in-process          0.2           -         1.0        25.9
research &
development
Amortization of              17.0        14.7        63.1        31.3
acquired intangibles
(incl. COS)
Relocation and                0.5         0.1         1.2         0.5
restructuring charges
SFAS 123R impact              3.1         2.4         9.4         5.8
(incl. COS)
Operating income,            66.6        51.8       252.7       164.3
adjusted

Net income, reported         24.7        15.0        89.0        50.1
Acquistion related            0.8         0.9         1.1         1.8
charges (COS)
Business integration          3.3         5.2        20.5         9.6
and related costs
Purchased in-process          0.2           -         1.0        25.9
research &
development
Relocation and                0.3           -         0.8         0.4
restructuring charges
Acquisition triggered           -           -         2.5           -
impairment
Amortization of              12.2         9.4        41.9        20.0
acquired intangibles
SFAS 123R impact              2.2         1.5         6.5         3.7
Net income, adjusted         43.7        32.0       163.3       111.5

Weighted average      202,039,000 205,233,000 204,259,000 175,959,000
number of diluted
common shares
EPS, reported in $           0.12        0.07        0.44        0.28
EPS, adjusted in $           0.22        0.16        0.80        0.63



"2008 was a  very successful  year for  QIAGEN in  which we  achieved
significant revenue growth, exceeding  our expectations. We  executed
on our strategy and significantly increased our technology and market
leadership in all  our target customer  segments", said Peer  Schatz,
QIAGEN's Chief Executive Officer. "The  launches of more than 80  new
products in 2008 contributed  5% to 2008 net  sales growth and are  a
testament to  QIAGEN's focus  on differentiating  by innovation.  New
products included innovative sample and assay technologies

  * For research in the application areas including epigenetics, gene
    expression, micro RNA, genotyping, RNAi;
  * For use in all customer segments, such as academia,
    pharmaceutical R&D, applied testing and molecular diagnostics;
    and
  * In the form of consumables and related instrumentation, such as
    the QIAsymphony SP - the first module of a novel modular
    processing platform integrating entire workflows in molecular
    processing - a new platform launch that we are very pleased with.

Our full pipeline  of new  products and a  strong strategic  position
build a solid basis for our success in 2009 and beyond."

 "We expect a number  of exciting new  market introductions in  2009.
These include a further expansion of our sample and assay  technology
portfolio for research in  applied testing and molecular  diagnostics
with the clear  goal of adding  even more regulated  products to  our
portfolio." Mr. Schatz  added. "Our pipeline  of automated  solutions
for our sample  and assay  technologies is  exceptionally strong.  In
January we already launched or announced several new products:

  * EZ1 Advanced XL, a fully automated sample technology system which
    can process and purify target analytes from up to 14 samples
    running on pre-programmed protocols and pre-filled cartridges;
  * QIAgility, a highly versatile assay set-up unit for assay
    technologies such as PCR;
  * Rotor-Gene Q, QIAGEN's new and technology leading real-time PCR
    cycler; and
  * The next module of QIAsymphony, QIAsymphony AS, a fully
    integrated assay set-up unit for the QIAsymphony platform which
    takes this platform one significant step closer towards being a
    fully integrated, random access and continuous load molecular
    testing solution."

"Our   acquisition   strategy   remains   focused,   consistent   and
value-creating, providing complementary technologies, new  commercial
capabilities  and/or  geographic  reach.  For  example,  we   further
strengthened our  market and  technology leadership  by adding  assay
technology set-up instrumentation  and real-time  PCR assay  analysis
technology  to   QIAGEN's   instrumentation  platform   through   the
acquisition of  Corbett in  July 2008.  With the  acquisition of  the
BioSystems business  from  Biotage  in October  2008,  we  added  the
Pyrosequencing  technology,  a   fundamental  assay  technology   for
high-resolution  sequence  detection   and  quantification  of   gene
variations which  we  believe will  play  a very  important  role  in
epigenetics as well as multiplex genetic and pathogen detection.  Our
molecular 'sample  to result'  solutions for  customers in  molecular
diagnostics, applied testing, pharma  and academic research, now  for
the first time span from sample to result across many different forms
of assay  detection  technologies -  from  qualitative/endpoint  PCR,
multiplex technologies and capillary electrophoresis to  quantitative
and high resolution, sequence-based analysis and cover a broad  range
of throughput needs."

"2008 was a very successful year for QIAGEN - we achieved our  strong
financial results while experiencing significant strategic  momentum.
I would  like to  thank  our employees  around  the world  for  their
contributions to our performance and their strong commitment to build
the basis for a long-term success for QIAGEN."

"QIAGEN experienced an exciting fourth quarter and fiscal year  2008.
Reported revenues  for the  fourth quarter  and for  the fiscal  year
exceeded our expectations. We experienced a strong adjusted operating
margin increase to 28% from 25% in fiscal year 2007 which corresponds
to a growth  rate of 54%  year over year  reflecting achievements  of
cost synergies  following the  acquisition  of Digene,"  said  Roland
Sackers, QIAGEN's Chief Financial Officer.

"Revenue growth for  fiscal year  2008 was 37%  and was  fueled by  a
strong organic  growth  of  13%  and  a  positive  contribution  from
acquisitions  of  22%   at  constant   currencies,"  Roland   Sackers
continued. "Our sample and assay portfolio grew 36% (34% at  constant
exchange rates) driven by strong growth  of sales of our products  to
customers in molecular diagnostics. QIAGEN's instrumentation business
recorded a very strong growth rate  of 51% (52% at constant  exchange
rates)  mainly  based  on  the  new  instruments  (QIAsymphonySP  and
QIAxcel) as well as a strong demand for the Rotor-Gene real-time  PCR
cycler and the CAS instrument following the Corbett acquisition.  Net
sales in the  Americas in  fiscal year  2008 represented  50% of  our
overall business and  recorded a  growth rate of  49% while  European
sales, which represent 37% of our  revenues, showed a growth rate  of
21% (17%  at constant  exchange rates).  Net sales  in Asia  remained
strong, showing  a  growth rate  of  24% (16%  at  constant  exchange
rates)."


Fiscal Year 2009 Guidance

Based on  foreign currency  exchange rates  as of  January 31,  2009,
QIAGEN expects revenues  between $920  and $970 million  in 2009  and
adjusted diluted earnings  per share between  $0.88 and $0.94.  Under
constant exchange rates consideration, revenue expectations for  2009
would be between $990 and $1,040  million with a growth rate  between
11% and  16% when  compared  to 2008  and expectations  for  adjusted
diluted  earnings  per  share  would  be  between  $0.92  and   $0.98
respectively.

Detailed information on the Company's business, financial performance
and expectations will be presented  in the Company's conference  call
on February 10,  2009 at  9:30am ET.  The corresponding  presentation
slides will be  available for  download on the  Company's website  at
www.qiagen.com/goto/ConferenceCall. A webcast of the conference  call
will     be     available     on     the     same     website      at
www.qiagen.com/goto/ConferenceCall.


QIAGEN - Sample and Assay Technologies Highlights:

* QIAGEN acquired Corbett Life Science Pty. Ltd., best known for the
  world's first rotary real-time PCR cycler system - the
  Rotor-Gene(TM) - a system used to detect and measure real-time
  polymerase chain reaction (PCR) reactions. The Corbett Rotor-Gene
  real-time PCR cycler is an excellent complement to QIAGEN's
  portfolio of current and future molecular testing solutions,
  including its modular processing platform QIAsymphony.

* QIAGEN acquired the BioSystems business from Biotage AB. The
  BioSystems unit of Biotage is best known for having pioneered
  Pyrosequencing®, which has become a fundamental technology in
  next-generation sequencing. In addition, in its widely used
  standard format (PyroMark systems and consumables) this technology
  provides the opportunity to read DNA-sequences up to 100 base pairs
  in real time, high-speed and with very low costs. The PyroMark
  solutions offer significant value for applications including
  Epigenetics in research and molecular diagnostics as well as in
  Multiplex analyses in genetic and pathogen detection.

* QIAGEN introduced the first molecular diagnostic test based on
  Pyrosequencing for the detection of mutations in the K-ras gene
  which is associated with the development of colon cancer. QIAGEN
  expects to launch further versions of this test in Europe
  (CE-marked) and in the U.S. very shortly.

* QIAGEN received additional 510(k) clearance from the U.S. Food and
  Drug Administration (FDA) for PreAnalytiX PAXgene(TM) Blood RNA
  System for use on QIAGENs QIAcube instrument. The PAXgene Blood RNA
  system, cleared by the FDA for manual use already in May 2005, is
  the first of its class for the collection, storage, and transport
  of blood and stabilization of intracellular RNA in a closed tube
  and subsequent isolation and purification of intracellular RNA from
  whole blood for Reverse Transcription-Polymerase Chain Reaction
  (RT-PCR) used in clinical and molecular diagnostic testing.

* The European Union launched a new research project led by QIAGEN
  targeting to expand the potential and utility of in-vitro
  diagnostics through the creation of new standards for the
  collection, handling and processing of blood, tissue, tumor and
  other sample materials. The SPIDIA project ("Standardisation and
  improvement of generic Pre-analytical tools and procedures for
  In-vitro DIAgnostics"), consisting of 16 companies and research
  institutions from 11 countries, is scheduled to run for four years
  and has a total budget of over 13 million Euros.

* In November 2008 the Mexican Public Health Agency (Secretaria de
  Salud or SSA) announced the launch of the first phase of a program
  that will offer testing for human papillomavirus (HPV). The cost of
  the testing will be covered by the agency. In the first phase of
  the screening program, more than 200,000 women were being offered
  the papillomavirus test along with the traditional Pap smear. In
  2009, the pilot program will be expanded to include another 600,000
  women in the 20 states with the highest death rate from cervical
  cancer. It is estimated that 6 million women a year will be
  eligible for HPV testing through the Mexican public health system
  once the screening program is national.



QIAGEN's Fiscal 2008 at
Constant Currencies

As percentage      FY 2008    FY 2008    FY 2007      Growth Rate
of net sales,                 Constant                      Constant
unless indicated   Reported   Currency  Reported  Reported  Currency

Consumables              88%        87%       89%       36%       34%
Instruments              11%        12%       10%       51%       52%
Others                    1%         1%        1%      -20%      -22%
Total revenues          100%       100%      100%       37%       35%

Gross margin             67%        67%       67%       38%       35%
Gross margin,            73%        72%       71%       41%       38%
adj.[1]

Operating income         16%        16%       13%       75%       71%
margin
Operating income         28%        28%       25%       54%       52%
margin, adj. [1]

Net income margin        10%        10%        8%       78%       71%
Net income               18%        18%       17%       47%       43%
margin, adj. [1],
[2]

EPS in US$ per          0.44       0.42      0.28       57%       50%
share
EPS in US$ per          0.80       0.78      0.63       27%       24%
share, adj. [1],
[2]

[1] excluding business integration and restructuring related charges
as well as
amortization of acquired intangibles and equity-based compensation.
[2] including a non-cash tax benefit of $0.02 per share in 2007 and
including a non-cash tax charge of $0.01 per share from revaluation
of acquired tax positions in 2008.



About QIAGEN:

QIAGEN   N.V.,    a    Netherlands   holding    company,    is    the
leading global provider of  sample  and  assay  technologies.  Sample
technologies are used to  isolate and process  DNA, RNA and  proteins
from biological samples such  as blood or tissue. Assay  technologies
are used  to  make such  isolated  biomolecules visible.  QIAGEN  has
developed and markets more than 500 sample and assay products as well
as automated solutions for such consumables. The company provides its
products to molecular diagnostics laboratories, academic researchers,
pharmaceutical   and    biotechnology    companies,    and    applied
testing customers for  purposes such  as forensics,  animal  or  food
testing   and   pharmaceutical   process   control. QIAGEN's    assay
technologies  include  one  of  the  broadest  panels  of   molecular
diagnostic tests available  worldwide. This panel  includes the  only
FDA-approved test for human  papillomavirus (HPV), the primary  cause
of cervical cancer. QIAGEN employs more than 3,000 people in over  30
locations worldwide. Further information about QIAGEN can be found at
www.qiagen.com.

Certain of  the statements  contained  in this  news release  may  be
considered forward-looking statements within  the meaning of  Section
27A of the U.S. Securities Act  of 1933, as amended, and Section  21E
of the  U.S. Securities  Exchange Act  of 1934,  as amended.  To  the
extent that  any  of  the statements  contained  herein  relating  to
QIAGEN's  products,  markets,  strategy  or  operating  results   are
forward-looking, such statements  are based  on current  expectations
that involve a number of uncertainties and risks. Such  uncertainties
and risks  include, but  are not  limited to,  risks associated  with
management of  growth  and international  operations  (including  the
effects  of  currency  fluctuations   and  risks  of  dependency   on
logistics),  variability   of  operating   results,  the   commercial
development of the applied testing markets, clinical research markets
and proteomics markets, women's  health/HPV testing markets,  nucleic
acid-based molecular diagnostics market, and genetic vaccination  and
gene  therapy   markets,  changing   relationships  with   customers,
suppliers and strategic  partners, competition,  rapid or  unexpected
changes in technologies, fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the level
and timing of  customers' funding, budgets,  and other factors),  our
ability to  obtain  regulatory  approval of  our  infectious  disease
panels, difficulties in  successfully adapting  QIAGEN's products  to
integrated solutions  and producing  such  products, the  ability  of
QIAGEN to identify and develop new products and to differentiate  its
products from competitors'  products, market  acceptance of  QIAGEN's
new  products  and  the  integration  of  acquired  technologies  and
businesses. For  further information,  refer  to the  discussions  in
reports that  QIAGEN  has  filed  with, or  furnished  to,  the  U.S.
Securities and Exchange Commission (SEC).

                                 ###



                             QIAGEN N.V.
             CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                             (unaudited)

                                                   Three months
(in thousands, except per share data)              ended December 31,

                                                2008          2007
Net sales                                   $   237,182   $   210,224
Cost of sales                                    65,518        58,572
Cost of sales - acquisition related               1,047         1,496
Cost of sales - acquisition related              13,166        11,359
intangible amortization
Gross profit                                    157,451       138,797

Operating expenses:
Research and development                         28,049        22,844
Sales and marketing                              59,662        56,230
General and administrative                       20,497        23,172
Purchased in-process research and                   155             -
development
Business integration and related costs            4,310         8,126
Acquisition related intangible amortization       3,884         3,354
Relocation and restructuring costs                  458            60
Total operating expenses                        117,015       113,786

Income from operations                           40,436        25,011

Other income (expense):
Interest income                                   2,121         3,669
Interest (expense)                              (8,695)      (11,099)
Other income, net                                 2,311         2,574
Total other (expense)                           (4,263)       (4,856)

Income before provision for income taxes         36,173        20,155
and minority interest
Provision for income taxes                       11,490         5,099
Minority interest loss                                -            56
Net income                                  $    24,683   $    15,000


Weighted average number of diluted common       202,039       205,233
shares

Diluted net income per common share         $      0.12   $      0.07


Diluted net income per common share
excluding acquisition, business integration
and restructuring
related charges as well as amortization of
acquired
intangibles and equity-based compensation   $      0.22   $      0.16
(SFAS 123R)






                             QIAGEN N.V.
             CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                             (unaudited)

                                                     Twelve months
(in thousands, except per share data)             ended December 31,

                                                      2008       2007
Net sales                                       $  892,975 $  649,774
Cost of sales                                      243,124    189,773
Cost of sales - acquisition related                  1,443      2,839
Cost of sales - acquisition related intangible      48,718     23,615
amortization
Gross profit                                       599,690    433,547

Operating expenses:
Research and development                            97,331     64,935
Sales and marketing                                227,408    164,690
General and administrative                          81,841     71,932
Purchased in-process research and development          985     25,900
Business integration and related costs              30,931     14,708
Acquisition related intangible amortization         14,368      7,711
Relocation and restructuring costs                   1,164        538
Total operating expenses                           454,028    350,414

Income from operations                             145,662     83,133

Other income (expense):
Interest income                                      9,511     19,509
Interest (expense)                                (37,527)   (31,455)
Other income, net                                    1,640      4,539
Total other (expense)                             (26,376)    (7,407)

Income before provision for income taxes and       119,286     75,726
minority interest
Provision for income taxes                          29,762     25,555
Minority interest loss                                 491         49
Net income                                      $   89,033 $   50,122


Weighted average number of diluted common          204,259    175,959
shares

Diluted net income per common share             $     0.44 $     0.28


Diluted net income per common share
excluding acquisition, business integration and
restructuring
related charges as well as amortization of
acquired
intangibles and equity-based compensation (SFAS $     0.80 $     0.63
123R)





                             QIAGEN N.V.
                CONDENSED CONSOLIDATED BALANCE SHEETS


(in thousands, except par value)            December 31, December 31,
                                                2008         2007
Assets                                      (unaudited)

Current Assets:
Cash and cash equivalents                    $   333,313  $   347,320
Marketable securities                                  -        2,313
Accounts receivable, net                         158,440      141,846
Income taxes receivable                            6,421       10,696
Inventories                                      108,563       88,346
Deferred income taxes                             31,258       23,732
Prepaid expenses and other                        61,424       33,693
Total current assets                             699,419      647,946

Long-Term Assets:
Property, plant and equipment, net               289,672      283,491
Goodwill                                       1,152,447    1,107,882
Intangible assets, net                           640,309      639,107
Deferred income taxes                             73,766       72,128
Other assets                                      25,916       24,620
Total long-term assets                         2,182,110    2,127,228

Total assets                                 $ 2,881,529  $ 2,775,174

Liabilities and Shareholders' Equity

Current Liabilities:
Current portion of long-term debt            $    25,000  $         -
Current portion of capital lease                   2,984        2,769
obligations
Accounts payable                                  48,836       40,379
Accrued and other liabilities                    163,513      104,224
Income taxes payable                               6,871       13,456
Deferred income taxes                              7,754        4,903
Total current liabilities                        254,958      165,731

Long-Term Liabilities:
Long-term debt, net of current portion           920,000      950,000
Capital lease obligations, net of current         29,718       33,017
portion
Deferred income taxes                            211,161      225,893
Other                                              6,797        8,405
Total long-term liabilities                    1,167,676    1,217,315

Minority interest in consolidated                      -          553
subsidiaries

Shareholders' Equity:
Common shares, EUR .01 par value:
Authorized--410,000 shares
Issued and outstanding--197,839 shares
in 2008 and 195,335 shares in 2007                 2,212        2,175
Additional paid-in-capital                       963,716      925,597
Retained earnings                                477,812      388,779
Accumulated other comprehensive income            15,155       75,024
Total shareholders' equity                     1,458,895    1,391,575

Total liabilities and shareholders' equity   $ 2,881,529  $ 2,775,174




Contacts:


Roland Sackers                           Dr. Solveigh Mähler
Chief Financial Officer                  Director Investor Relations
QIAGEN N.V.                              QIAGEN N.V.
E-mail: [e-mail]        [phone]
                                         E-mail:
Albert F. Fleury                         [e-mail]
Director Corporate Finance and Investor
Relations North America                  Dr. Thomas Theuringer
QIAGEN N.V.                              Associate Director Public
[phone]                          Relations
E-mail: [e-mail]         QIAGEN GmbH
                                         [phone]
                                         E-mail:
                                         [e-mail]


 
--- End of Message ---

Qiagen N.V.
Spoorstraat 50 KJ Venlo Netherlands

WKN: 901626; ISIN: 
NL0000240000; Index: HDAX, MIDCAP, Prime All Share, TECH All Share, 
TecDAX;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in 
Börse Berlin, 
Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische 
Wertpapierbörse zu Hamburg, 
Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in 
Bayerische Börse München, 
Freiverkehr in Börse Stuttgart;